Novartis Pelacarsen Fails Phase III Lp(a) Trial

Pelacarsen's failure to reduce major adverse cardiovascular events in the Lp(a)HORIZON Phase III trial closes the most advanced clinical pathway for antisense oligonucleotide (ASO)-based Lp(a) intervention and raises immediate questions about the manufacturing and supply commitments Novartis holds under its license and collaboration agreement with Ionis Pharmaceuticals.

Novartis announced on September 4, 2026, that the randomized, placebo-controlled, double-blind trial, enrolling 8,323 patients with elevated Lp(a) and established CVD across a global multi-center design, did not meet its primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. The result held across both the overall population (Lp(a) ≥70 mg/dL) and the pre-specified subpopulation (Lp(a) ≥90 mg/dL). Pelacarsen did achieve measurable Lp(a) reduction, confirming pharmacological activity, but that reduction did not translate into clinical benefit against a background of guideline-directed lipid-lowering and antihypertensive therapy.

For QA directors and plant heads with ASO manufacturing exposure, the operational read is direct: dedicated capacity built or reserved for pelacarsen commercial-scale production now requires reassessment. ASO synthesis operates under tightly validated process parameters, and any reallocation of suite capacity or raw-material commitments will need to run through formal change-control procedures consistent with 21 CFR Part 211 and ICH Q10 quality system requirements. Contract manufacturers supporting the Ionis collaboration asset network face analogous decisions around campaign scheduling and technology-transfer obligations.

The scientific implication is equally consequential for the broader Lp(a) field. Lp(a) is an inherited risk factor affecting approximately one in five people globally, with no approved targeted therapy. Lp(a)HORIZON (NCT04023552) was designed specifically to determine whether biochemical Lp(a) reduction translates into reduced residual cardiovascular risk on top of optimized standard of care, a question that now carries a negative answer for this molecule and this trial design. Competing programs targeting Lp(a) through different mechanisms will need to account for these findings in their own endpoint selection and patient-stratification strategies.

Full trial data are expected to be presented at an upcoming medical congress, where subgroup analyses may clarify whether any patient segment showed differential benefit, information that regulatory affairs leads should monitor closely before drawing conclusions about the broader ASO cardiovascular development landscape.

The pace at which Novartis and Ionis formally address capacity and collaboration obligations under their licensing agreement will serve as a measurable indicator of how quickly the industry can realign ASO manufacturing infrastructure following a large-scale Phase III discontinuation.

Source: Novartis via GlobeNewswire, September 4, 2026.